Procaps Group S.A
PROC
Get informed when a big investor buys or sells
+ FollowMarket Cap$102.08M
Close$
$8.18
709.8% upside
Current Fair Value
709.8% upsideUndervalued by 709.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $102.08 Million |
|---|---|
| Enterprise Value | $413.88 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.42 |
| Beta | 0.17 |
| Outstanding Shares | 102,425,000 |
Return
| Return on Equity | 19211.43% |
|---|---|
| Return on Assets | 8.54% |
| Return on Invested Capital | 73.40% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | 0.25 |
| Price to Book Ratio | -1.01 |
| Enterprise Value to Revenue | 0.98 |
| Enterprise Value to EBIT | 7.96 |
| Enterprise Value to Net Income | 10 |
| Total Debt to Enterprise | 0.8 |
| Debt to Equity | 1568.16 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Procaps Group S.A
4,498 employees
CEO: Ruben Minski Procaps Group S.A. is a global pharmaceutical company engaged in the development, manufacturing, and commercialization of a diverse range of medical solutions. The company's portfolio encompasses branded prescription drugs, addressing nu...